ASSESSMENT OF LIVER FUNCTION IMPAIRMENT AND ITS IMPACT ON SYMPTOMATIC COVID-19 INFECTED PATIENTS

MA RANA; U ASLAM; H ALI; MA BHATTI; MS KHALID; AHA AWAD; A CHOUDHARY; MM HAFEEZ

doi:10.54112/bcsrj.v2022i1.118

Authors

MA RANA Department of Critical Care, Division of Medicine, Amna Inayat Medical College Sheikhupura / Intensivist Bahria International Hospital, Lahore
U ASLAM Department of Medicine, Fatima Jinnah Medical University, Lahore, Pakistan
H ALI Department of Physiology, Aziz Fatima Medical and Dental College, Faisalabad, Pakistan
MA BHATTI Department of Gastroenterology and Hepatology, Amna Inayat Medical College Sheikhupura, Pakistan
MS KHALID Department of Gastroenterology, Continental Medical College, Lahore, Pakistan
AHA AWAD Department of Critical Care, Rashid Hospital Dubai, UAE
A CHOUDHARY Department of Hematology, Shaikh Zayed Hospital Lahore, Pakistan
MM HAFEEZ Director Research and Development Expert Doctors, PVT, LTD, Lahore, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2022i1.118

Keywords:

COVID-19, Liver function test, Mortality, Liver damage

Abstract

It is noted in literature that a significant number of COVID-19 infected patients had abnormal liver enzyme values as the disease progressed. Studies have shown a higher prevalence of hepatic impairment in patients with severe COVID-19. This study was designed to assess the variation of liver function test in COVID-19 patients and their relation to the severity of the illness. The secondary outcome of the study was the length of hospital stay and mortality assessment. This study was conducted at Bahira town international hospital Lahore from September 1, 2020, to September1, 2021. A total of 169 participants were included in the cross-sectional study those who meet the inclusion criteria. In this study we assessed the records of 169diagnosed cases of COVID-19 Infection on RT-PCR, and data were analyzed. They were further divided into two groups. First with abnormal liver function tests (LFT) and second Group consisted of normal LFTs. Liver function tests including total bilirubin, Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, were recorded and liver dysfunction was labeled if any of the parameters were found to be elevated from the normal physiological range. A total of 236 COVID-19 individuals were examined during the one-year duration. Of those, 169 were found to be eligible, but 67 were disqualified because they had a history of hepatitis B and C or previous history of liver disease. The Abnormal liver function tests group included 81 participants whereas second group with normal LFTs had 88 participants. Patients with severe illnesses were more affected by liver malfunction than those with moderate illnesses. Patients with liver dysfunction required a longer stay in the hospital on average than patients with healthy livers did. Patients who had normal LFT at admission had a cure rate of 95.06%, while 4.94% of them passed away, whereas 18.18% of patients passed away in abnormal liver function test. Liver function derangement is frequent in individuals with severe COVID-19, and it can be brought on directly by a virus that damages the bile duct cells or indirectly by a cytokine storm and lead to increased mortality and length of hospital stay.

Downloads

Download data is not yet available.

References

Alqahtani, S. A., and Schattenberg, J. M. (2020). Liver injury in COVID-19: The current evidence. United European Gastroenterology Journal 8, 509-519.

Cai, Q., Huang, D., Ou, P., Yu, H., Zhu, Z., Xia, Z., Su, Y., Ma, Z., Zhang, Y., and Li, Z. (2020a). COVID‐19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy 75, 1742-1752.

Cai, Q., Huang, D., Yu, H., Zhu, Z., Xia, Z., Su, Y., Li, Z., Zhou, G., Gou, J., and Qu, J. (2020b). COVID-19: Abnormal liver function tests. Journal of Hepatology 73, 566-574.

Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., and Wei, Y. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 395, 507-513.

Ciardullo, S., Zerbini, F., Perra, S., Muraca, E., Cannistraci, R., Lauriola, M., Grosso, P., Lattuada, G., Ippoliti, G., and Mortara, A. (2021). Impact of diabetes on COVID-19-related in-hospital mortality: a retrospective study from Northern Italy. Journal of Endocrinological Investigation 44, 843-850.

Gholizadeh, P., Safari, R., Marofi, P., Zeinalzadeh, E., Pagliano, P., Ganbarov, K., Esposito, S., Khodadadi, E., Yousefi, M., and Kafil, H. S. (2020). Alteration of liver biomarkers in patients with SARS-CoV-2 (COVID-19). Journal of Inflammation Research 13, 285.

Guan, W.-j., Ni, Z.-y., Hu, Y., Liang, W.-h., Ou, C.-q., He, J.-x., Liu, L., Shan, H., Lei, C.-l., and Hui, D. S. (2020). Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine 382, 1708-1720.

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., and Gu, X. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 395, 497-506.

Jose, R. J., and Manuel, A. (2020). COVID-19 cytokine storm: the interplay between inflammation and coagulation. The Lancet Respiratory Medicine 8, e46-e47.

Mohanty, S. K., Satapathy, A., Naidu, M. M., Mukhopadhyay, S., Sharma, S., Barton, L. M., Stroberg, E., Duval, E. J., Pradhan, D., and Tzankov, A. (2020). Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19)–anatomic pathology perspective on current knowledge. Diagnostic Pathology 15, 1-17.

Nikpouraghdam, M., Farahani, A. J., Alishiri, G., Heydari, S., Ebrahimnia, M., Samadinia, H., Sepandi, M., Jafari, N. J., Izadi, M., and Qazvini, A. (2020). Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study. Journal of Clinical Virology 127, 104378.

Radivojevic, A., Jad, A. A. A., Ravanavena, A., Ravindra, C., Igweonu-Nwakile, E. O., Ali, S., Paul, S., Yakkali, S., Selvin, S. T., and Thomas, S. (2022). A Systematic Review of SARS-CoV-2-Associated Hepatic Dysfunction and the Impact on the Clinical Outcome of COVID-19. Cureus14.

Rotondi, M., Coperchini, F., Ricci, G., Denegri, M., Croce, L., Ngnitejeu, S., Villani, L., Magri, F., Latrofa, F., and Chiovato, L. (2021). Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis. Journal of Endocrinological Investigation 44, 1085-1090.

Shi, H., Han, X., Jiang, N., Cao, Y., Alwalid, O., Gu, J., Fan, Y., and Zheng, C. (2020). Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. The Lancet Infectious Diseases 20, 425-434.

Wang, J.-T., Sheng, W.-H., Fang, C.-T., Chen, Y.-C., Wang, J.-L., Yu, C.-J., Chang, S.-C., and Yang, P.-C. (2004). Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerging Infectious Diseases 10, 818.

Yang, X., Yu, Y., Xu, J., Shu, H., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., and Yu, T. (2020). Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine 8, 475-481.

Zhang, C., Shi, L., and Wang, F.-S. (2020). Liver injury in COVID-19: management and challenges. The lancet Gastroenterology & Hepatology 5, 428-430.

Zhao, X., Lei, Z., Gao, F., Xie, Q., Jang, K., and Gong, J. (2021). The impact of coronavirus disease 2019 (COVID-19) on liver injury in China: a systematic review and meta-analysis. Medicine 100.

Zuin, M., Rigatelli, G., Bilato, C., Cervellati, C., Zuliani, G., and Roncon, L. (2021). Prognostic role of metabolic syndrome in COVID-19 patients: a systematic review meta-analysis. Viruses 13, 1938.